Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus

Grando, Aline Vitali; Ferreira, Paulo Roberto Abrão; Mazo, Daniel Ferraz de Campos; Brandão‐Mello, Carlos Eduardo; Reuter, Tânia; Martinelli, Ana de Lôurdes Candolo; Gonzalez, Mario P; Nastri, Ana Catharina de Seixas Santos; Campos, Aléia Faustina; Lopes, Max Igor Banks Ferreira; Brito, José David Urbáez; Mendes-Corrêa, Maria Cássia

doi:10.1590/s1678-9946201759067

Cited by 3 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SVR in test group based on genotype distribution was found of 100% in all genotypes except of G4 - 85.7%. SVR among IVDU with G3 noticed 54.6% to 91% (21, 31, 34) but in the study of the maior IVDU population HCV monoinfected and co-infected with HIV SVR was reported by 60.5% and 51.4% (35).…”

Section: Discussionmentioning

confidence: 91%

“…Brasillian authors the most higher SVR were noticed among patients with F3 (67%) then with F0 and F1 (59%) (35). By multivariant regressive analyses Marcellin and al.…”

Section: Discussionmentioning

confidence: 91%

“…Important predictive factors for SVR were age, male, reduction of peg-interferon and ribavirin, stage of fibrosis and EVR. As it is reported in the literature treatment of chronic HCV by peg-interferon/ ribavirin still present acceptable treatment option besides better treatment choice (35). That is important for the countries where DAA treatment wasn’t completely implemented.…”

Section: Resultsmentioning

confidence: 99%

“…Study which included 118 centers in USA reported significant statistical difference in EVR (p=0.01), ETR (p< 0.001), but in SVR there was no statistical significant difference (p=0.57) between the same treatment options (36). In the paper of brasilian authors peg- interferon α 2b was in negative association with SVR attainment (35).…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Quality of Life Assessment in Antidepressant Treatment of Patients with Depression and/Or Anxiety Disorder

et al. 2018

View full text Add to dashboard Cite

Introduction: Chronic HCV infection is chronic inflamatory liver disease caused by hepatitis C virus. Anti HCV prevalence among intravenous drug users (IVDU) is very high and it accounts 40% -90% (60%-90%) with the risk of 80% of developing the chronic infection. Aim: The aims of this study were: a) to compare clinical characteristics of chronic HCV infection among IVDU and non-users population and to detect their impact to treatment outcome; b) to investigate the treatment efficacy comparing sustained viral response (SVR) in these two populations in Tuzla Canton. Patients and methods: The study was retrospective-prospective and included 45 IVDU of both sexes from Tuzla Canton which were treated from chronic HCV infection with Pegilated interferon 2a/2b + ribavirin in the Clinic for Infectious Diseases and Clinic for Internal Disease of University Clinical Centre in Tuzla. The control group were presented by non-users who completed therapy in both Clinics. For statistical analyses it was used statistical package SPSS 20,0 (SPSS Inc, Chicago, IL, USA) with tests of descriptive statistics with measures of central tendency and dispersion. Quantitative variables were tested by t-test or by Mann-Whitney test. Qualitative variables were tested by hi-square test or by Fisher’s test. The standard analyse of level’s risk was used too. The analyse of predictive value of EVR for achieving the ETR and SVR was done by cross-tabulation. The impact of known factors for achieving the SVR was evaluated by logistic regression analyses. All tests were done with statistical level of significance of 95% (p=0,05). Results: Men were more dominant in the test group (93,3% / 61,7%), also younger age (p<0,001) and lower BMI (p=0,019). The test group had significant higher basal values of Le, Hb, Plt and ALT and tendency to lower stages of fibrosis (p=0,08). The difference in genotype frequencies was statistically significant (p=0,001) with clearly dominance of G3 and G4 among IVDU. Treatment was not complited by two patients in both groups (4,4% /3,3%). EVR was significantly higher in test group (p=0,001) so did the ETR (p=0,002) and SVR (p<0,001). Predictive factors for SVR were: age (negative predictive factor), male sex, absence of reduction of pegilated interferon and ribavirin, Metavir stage of fibrosis and presence of EVR. Conclusion: Population of IVDU were adherent to treatment protocol and with excellent treatment response they justified the hope of health care workers for success treatment of this population.

show abstract

Section: Discussionmentioning

confidence: 91%

“…Brasillian authors the most higher SVR were noticed among patients with F3 (67%) then with F0 and F1 (59%) (35). By multivariant regressive analyses Marcellin and al.…”

Section: Discussionmentioning

confidence: 91%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Quality of Life Assessment in Antidepressant Treatment of Patients with Depression and/Or Anxiety Disorder

et al. 2018

View full text Add to dashboard Cite

show abstract

Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations

Rentiya

Wells

Bae

et al. 2018

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil

Lourenço¹,

Zitelli²,

Cunha‐Silva³

et al. 2022

WJH

View full text Add to dashboard Cite

BACKGROUND Hepatitis C virus (HCV) treatment has undergone major changes in recent years. Previous interferon-based therapies have been replaced by oral direct-acting antivirals (DAA) regimens, with high sustained virologic response (SVR) rates, and a lower incidence of adverse events (AEs). AIM To evaluate the efficacy and safety of DAAs for HCV treatment in subjects from two tertiary university centers in Brazil. METHODS This is a multicenter retrospective cohort study of 532 patients with chronic hepatitis C (CHC), undergoing treatment with interferon-free regimens from November 2015 to November 2019. The therapeutic regimen was defined by the current Brazilian guidelines for HCV management at the time of treatment. Demographic, anthropometric, clinical, and laboratory variables were evaluated. SVRs were assessed at 12 to 24 wk after therapy by intention-to-treat (ITT), and modified ITT (m-ITT) analysis. AEs and serious adverse events (SAEs) were registered. In the statistical analysis, a P value of < 0.05 was considered significant. RESULTS The mean age was 56.88 years, with 415 (78.5%) being HCV genotype 1, followed by genotype 3 (20.1%). Moreover, 306 (57.5%) subjects had cirrhosis, and a third of them had decompensated cirrhosis. Sofosbuvir (SOF) plus daclatasvir ± ribavirin was the most frequently used treatment (66.9%), followed by SOF plus simeprevir (21.2%). The overall ITT SVR was 92.6% (493/532), while the m-ITT SVR was 96.8% (493/509). Variables associated with treatment failure via ITT evaluation were hepatic encephalopathy (OR: 4.320; 95%CI: 1.920-9.721, P = 0.0004), presence of esophageal varices (OR: 2.381; 95%CI: 1.137-4.988, P = 0.0215), previous portal hypertensive bleeding (OR: 2.756; 95%CI: 1.173-6.471, P = 0.02), higher model for end-stage liver disease scores (OR: 1.143, 95%CI: 1.060–1.233, P = 0.0005), lower serum albumin levels (OR: 0.528, 95%CI: 0.322-0.867, P = 0.0115), higher serum creatinine (OR: 1.117, 95%CI: 1.056-1.312, P = 0.0033), and international normalized ratio (INR) levels (OR: 5.542, 95%CI: 2.023-15.182, P = 0.0009). AEs were reported in 41.1% (211/514) of patients, and SAEs in 3.7%. The female gender, higher body mass index, esophageal varices, higher INR values, and longer treatment duration were independently associated with AE occurrence. CONCLUSION Treatment with oral DAAs attains a high SVR rate, with fewer SAEs in a real-life cohort of subjects with CHC, from two tertiary university centers in Brazil.

show abstract

Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus

Cited by 3 publications

References 27 publications

Quality of Life Assessment in Antidepressant Treatment of Patients with Depression and/Or Anxiety Disorder

Quality of Life Assessment in Antidepressant Treatment of Patients with Depression and/Or Anxiety Disorder

Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations

Direct-acting antivirals for chronic hepatitis C treatment: The experience of two tertiary university centers in Brazil

Contact Info

Product

Resources

About